-
公开(公告)号：US20220002380A1
公开(公告)日：2022-01-06
申请号：US17294582
申请日：2019-10-29
IPC: C07K14/705 , A61K39/00
Abstract: The present invention provides improved Etanercept variants which comprise one (A105E), preferably two (A105E/L106F), amino acid substitutions regarding the Etanercept original amino acid sequence of SEQ ID NO: 3. These variants inhibit TNF activity but fail to neutralize human LTα (hLTα). Thus, they are proposed herein as a great alternative to be used in the clinic for the treatment of autoimmune or inflammatory diseases in which an exacerbated TNF activity is involved, since they prevent the side effects associated to the use of the original Etanercept molecule while retaining the TNF blocking activity.
Search Results
1
records
(took 0.013 seconds)
筛选
AND
AND
过滤
NOT
NOT
Scan to Join
